Last reviewed · How we verify
Solifenacin + Mirabegron
Solifenacin and mirabegron work synergistically to reduce overactive bladder symptoms by blocking muscarinic receptors (solifenacin) and activating beta-3 adrenergic receptors (mirabegron) to decrease detrusor muscle contractions and increase bladder capacity.
Solifenacin and mirabegron work synergistically to reduce overactive bladder symptoms by blocking muscarinic receptors (solifenacin) and activating beta-3 adrenergic receptors (mirabegron) to decrease detrusor muscle contractions and increase bladder capacity. Used for Overactive bladder with symptoms of urgency, frequency, and urgency incontinence.
At a glance
| Generic name | Solifenacin + Mirabegron |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Antimuscarinic + Beta-3 adrenergic agonist combination |
| Target | M3 muscarinic receptor (solifenacin) and beta-3 adrenergic receptor (mirabegron) |
| Modality | Small molecule |
| Therapeutic area | Urology / Neurology |
| Phase | FDA-approved |
Mechanism of action
Solifenacin is an antimuscarinic agent that blocks M3 receptors on bladder smooth muscle, reducing involuntary contractions. Mirabegron is a beta-3 adrenergic agonist that relaxes the detrusor muscle during the storage phase of the bladder. Together, they provide dual mechanism action targeting both parasympathetic and sympathetic pathways to improve bladder storage capacity and reduce urgency and frequency.
Approved indications
- Overactive bladder with symptoms of urgency, frequency, and urgency incontinence
Common side effects
- Dry mouth
- Constipation
- Headache
- Hypertension
- Urinary retention
- Blurred vision
Key clinical trials
- Mirabegron in Patients With Age-Related Macular Degeneration
- Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
- Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry) (PHASE4)
- Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) (PHASE3)
- Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (NA)
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (PHASE3)
- Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms (PHASE3)
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Solifenacin + Mirabegron CI brief — competitive landscape report
- Solifenacin + Mirabegron updates RSS · CI watch RSS
- University of Aarhus portfolio CI